This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.
1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors
ePostersLive by SciGen Technologies S.A. All rights reserved.
September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas
MM - 1252
Multiple Myeloma (MM)
REAL-WORLD OUTCOMES OF TALQUETAMAB IN MONUMENTAL-1 TRIAL-INELIGIBLE VERSUS TRIAL-ELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
J. Ramirez 1, R. Darji1, C. Wright1, K. Neupane 2, K. Harada 2, A. Dixon 2, B. Blue2, C. Freeman 2, F. Locke 2, T. Nishihori 2, J. Eatrides 2, L. Gardner 2, R. Baz 2, M. Alsina2, K. Shain 2, O. Castaneda 2, D. Hansen 2, A. Grajales-Cruz2
1. University of South Florida Morsani College of Medicine, Tampa, FL, USA
2. H. Lee Moffitt Cancer Center, Tampa, FL, USA
INTRODUCTION
Talquetamab is a GPRC5D × CD3 bispecific T-cell engager with demonstrated activity in heavily pretreated RRMM in the MonumenTAL-1 study. The efficacy of talquetamab among patients who would have been trial-ineligible, particularly after prior BCMA-directed therapy, remains clinically relevant as T-cell-redirecting therapies are used earlier in the treatment course.
Primary Objective
Compare talquetamab efficacy by retrospective MonumenTAL-1 eligibility
Secondary Objective
Evaluate outcomes after prior BCMA-directed therapy and describe real-world safety and treatment feasibility
METHODS:
Design: Single-center retrospective cohort
Setting: Moffitt Cancer Center, May 2023–November 2025
Population: 95 patients with RRMM; CAR-T bridging cases excluded
MonumenTAL-1 eligibility retrospectively adjudicated using published criteria
Responses assessed per IMWG criteria
Primary endpoint: ORR
Secondary endpoints: PFS, OS, DOR, safety
Kaplan-Meier/log-rank for time-to-event outcomes; Fisher’s exact test for ORR
CONCLUSIONS
85.3% of patients would not have met MonumenTAL-1 eligibility criteria despite largely preserved performance status (96.8% ECOG ≤2).
ORR was preserved across eligibility groups; PFS and OS were unexpectedly longer among patients who would not have met trial criteria.
Survival differences are hypothesis-generating given the marked group imbalance (n = 14 vs n = 81) and potential physician treatment selection/selection bias.
SAFETY AND REAL WORLD FEASIBILITY
CRS: 38/95 patients (40.0%)
Grade ≥3 CRS: 3/95 (3.2%)
Median CRS grade: 2
Mean CRS-related hospitalization: 2.9 days
Prophylactic tocilizumab administered: 38/95
16 patients underwent outpatient step-up initiation
13/16 (81.3%) outpatient patients received prophylactic tocilizumab
No statistically significant difference in PFS or OS by prior BCMA exposure
ORR was similar between patients who would and would not have met the MonumenTAL-1 eligibility criteria.